ストックスクリーナーアプリを入手
9.25
3.75%
-0.36
プレマーケット:
9.25
Day One Biopharmaceuticals Inc (DAWN) 最新ニュース
Trading Action: Is Day One Biopharmaceuticals Inc. stock a good choice for value investorsWall Street Watch & Technical Buy Zone Confirmation - ulpravda.ru
Will Day One Biopharmaceuticals Inc. stock benefit from automation2025 Bull vs Bear & Free Accurate Trade Setup Notifications - ulpravda.ru
Day One Biopharmaceuticals completes acquisition of Mersana Therapeutics - Investing.com
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics - TipRanks
Day One Biopharmaceuticals Signs Contingent Value Rights Agreement With Computershare - TradingView — Track All Markets
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics to Enhance Oncology Pipeline - Quiver Quantitative
Day One Completes Acquisition of Mersana Therapeutics - GlobeNewswire
Day One Biopharmaceuticals (NASDAQ:DAWN) Nasdaq Index Biomarker Science - Kalkine Media
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
(DAWN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
When Can We Expect A Profit From Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)? - 富途牛牛
How The Mersana Deal Is Rewriting The Story Behind Day One Biopharmaceuticals Valuation - Yahoo Finance
Is Day One Biopharmaceuticals Inc. stock dividend yield sustainableJuly 2025 Trends & Growth Focused Stock Pick Reports - Улправда
Price-Driven Insight from (DAWN) for Rule-Based Strategy - Stock Traders Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 6%What's Next? - MarketBeat
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth - Sahm
Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026I'm Bullish (NASDAQ:DAWN) - Seeking Alpha
Day One Biopharmaceuticals (NASDAQ:DAWN) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Day One Biopharmaceuticals Reports Promising FIREFLY-1 Trial Results - timothysykes.com
FuelCell Energy Posts Strong Q4 Results, Joins Trump Media & Technology, Micron Technology, Lululemon And Other Big Stocks Moving Higher On Thursday - Sahm
Day One Biopharmaceuticals (NASDAQ:DAWN) Gains Visibility Nasdaq Today - Kalkine Media
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 5.5%Still a Buy? - MarketBeat
Day One Biopharmaceuticals Target of Unusually Large Options Trading (NASDAQ:DAWN) - MarketBeat
Day One Biopharma (DAWN) announces positive 3-year follow-up results from pivotal phase 2 FIREFLY-1 trial of OJEMDA (tovorafenib) - MSN
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Hudson Bay Capital Management LP Has $8.43 Million Holdings in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Day One Biopharma (DAWN) Announces Positive 3-Year Follow-up Results from Pivotal Phase 2 FIREFLY-1 Trial of OJEMDA (Tovorafenib) - Finviz
20 Stocks That Will Double in 2026 - Insider Monkey
Halper Sadeh LLC Encourages FFWM, MRSN, FSUN Shareholders to Contact the Firm to Discuss Their Rights - FinancialContent
Braidwell LP Has $14.18 Million Position in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Day One Biopharmaceuticals Reports Strong Q3 2025 Results - MSN
Day One Biopharmaceuticals Inc. (DAWN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Day One Biopharmaceuticals Reports Strong Q3 2025 Growth - MSN
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 4.9%What's Next? - MarketBeat
Why The Narrative Around Day One Biopharmaceuticals Is Shifting After The Mersana Acquisition - Yahoo Finance
Day One Biopharmaceuticals Expands with Mersana Acquisition - StocksToTrade
Day One Biopharmaceuticals (NASDAQ:DAWN) Sees Large Volume IncreaseTime to Buy? - MarketBeat
(DAWN) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Day One’s FIREFLY Trial Shows Promise in Pediatric Cancer Treatment - timothysykes.com
Day One Biopharmaceuticals (NASDAQ:DAWN) Nasdaq Futures Clinical-Stage Innovation - Kalkine Media
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
180,133 Shares in Day One Biopharmaceuticals, Inc. $DAWN Bought by Schroder Investment Management Group - MarketBeat
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal - MSN
How buybacks impact Day One Biopharmaceuticals Inc. stock valueTrade Performance Summary & Verified High Yield Trade Plans - Newser
Day One to buy Mersana Therapeutics for $25/share upfront - MSN
Day One Biopharmaceuticals, Inc. $DAWN Shares Purchased by Geode Capital Management LLC - MarketBeat
Updated FIREFLY-1 Data Further Support Tovorafenib as a SOC in R/R Pediatric Low-Grade Glioma - OncLive
Will Day One Biopharmaceuticals Inc. stock deliver shareholder valueJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - Newser
Day One Biopharmaceuticals, Inc. $DAWN Shares Purchased by Virtus Investment Advisers LLC - MarketBeat
Franklin Resources Inc. Purchases 79,255 Shares of Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
What drives Day One Biopharmaceuticals Inc stock pricePrice Momentum Alerts & Investor Community Interactions - earlytimes.in
0.80%
4.56%
大文字化:
|
ボリューム (24 時間):